NPM1 MUTATION

CI-VAR-00002636Explore in graph →CIViC 3138

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia4
NPM1 MUTATION	(diagnostic)	Diagnostic	A	Supports Positive	5	submitted	EID8596 In the the 2008 World Health Organization (WHO) classification of acute myeloid leukemia (AML), AML with mutated NPM1 was considered as a provisional entity. In the updated 2016 WHO classification , A… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic
NPM1 MUTATION	Revumenib	Predictive	B	Supports Sensitivity Response	4	submitted	EID12743 Results from phase II of the AUGMENT-101 trial are reported for patients with NPM1 mutant relapsed/refractory AML (≥3 previous lines of therapy) treated with revumenib. Patients received revumenib wit… (full text at CIViC) PMID 40332046 · Arellano et al., 2025 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Acute Myeloid Leukemia with NPM1 Mutation3
NPM1 MUTATION	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID108 In this publication, the role of NPM1 mutations in defining a distinct subset of acute myeloid leukemia (AML) was investigated. Among 1,485 adult AML patients enrolled in the multicenter AML96 protoco… (full text at CIViC) PMID 16455956 · Thiede et al., 2006 · Open in CIViC	civic
NPM1 MUTATION	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12494 In this 2005 study, immunohistochemical staining was used to assess the subcellular localization of NPM in 1,835 paraffin-embedded tumor specimens, including 591 from primary AML patients (ages 15–60)… (full text at CIViC) PMID 15659725 · Falini et al., 2005 · Open in CIViC	civic
NPM1 MUTATION	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID12495 In this 2005 study, the authors investigated the prevalence and prognostic impact of NPM1 mutation status in 300 adult patients with AML (16-60 years of age) with normal cytogenetics. The diagnostic b… (full text at CIViC) PMID 16051734 · Döhner et al., 2005 · Open in CIViC	civic